Intravenous or subcutaneous natalizumab in patients with relapsing –remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study

ConclusionsSC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs.
Source: Journal of Neurology - Category: Neurology Source Type: research